Package Leaflet: Information for the Patient
Lonquex 6 mg/0.6 ml Solution for Injection
lipegfilgrastim
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.
Contents of the Package Leaflet
What is Lonquex
Escherichia coli.
It belongs to a group of proteins called cytokines and is similar to a natural protein (granulocyte-colony stimulating factor [G-CSF]) produced by your own body.
What Lonquex is used for
Your doctor has prescribed Lonquex to you or your child to reduce the duration of a condition called neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with fever). These problems can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells).
How Lonquex works
Do not use Lonquex:
Warnings and precautions
Talk to your doctor, pharmacist or nurse before starting Lonquex.
Your doctor will perform regular blood tests to monitor various components of your blood and their concentrations. Your doctor will also periodically check your urine or your child's urine, as other medicines similar to this one (e.g. other granulocyte-colony stimulating factors such as filgrastim, lenograstim or pegfilgrastim) may damage the small filters in the kidneys (glomerulonephritis; see section 4 “Possible side effects”).
Rarely, inflammation of the aorta (the large blood vessel that carries blood from the heart to the rest of the body) has been reported with other medicines like this one (e.g. filgrastim, lenograstim or pegfilgrastim from the G-CSF group). Symptoms may include fever, abdominal pain, general malaise, back pain, and increased inflammatory markers. Tell your doctor if you experience these symptoms.
Children and adolescents
Other medicines and Lonquex
Tell your doctor or pharmacist if you or your child is using, has recently used or might use any other medicines.
Pregnancy and breastfeeding
It is not known whether the active substance of this medicine passes into breast milk. Therefore, you should stop breastfeeding during treatment.
Driving and using machines
The influence of Lonquex on your ability to drive and use machines is negligible or nil.
This medicine contains 30 mg of sorbitol in each vial.
This medicine contains less than 1 mmol of sodium (23 mg) per vial, i.e. it is essentially “sodium-free”.
What is the recommended dose
The recommended dose in adults is 6 mg (one 0.6 ml vial) once per chemotherapy cycle.
The recommended dose in children and adolescents is based on their body weight:
Body weight (kg) | Dose (once per chemotherapy cycle) |
< 10 | 0.6 mg (0.06 ml) |
≥ 10 to < 20 | 1.5 mg (0.15 ml) |
≥ 20 to < 30 | 2.5 mg (0.25 ml) |
≥ 30 to < 45 | 4.0 mg (0.40 ml) |
≥ 45 | 6.0 mg (0.60 ml) |
When will Lonquex be administered
The dose of Lonquex will usually be injected approximately 24 hours after the last dose of chemotherapy, at the end of each chemotherapy cycle.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
More serious side effects
These may be symptoms of a condition called “capillary leak syndrome”, which causes blood to leak from small blood vessels in your body and requires urgent medical attention.
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from the available data)
Side effects that have been seen with similar medicines, but not yet with Lonquex
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer packaging and on the label of the vial after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Keep the vial in the outer packaging to protect it from light.
Do not use this medicine if it is cloudy or contains particles.
Composition of Lonquex
Appearance and packaging of the product
Not all pack sizes may be marketed.
Marketing authorisation holder
Teva B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
Manufacturer
Teva Biotech GmbH
Dornierstraße 10
89079 Ulm
Germany
Merckle GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany
You can get more information about this medicine from your local representative of the marketing authorisation holder:
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG Tel: +32 38207373 | Lietuva UAB Teva Baltics Tel: +370 52660203 |
| Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien Tel: +32 38207373 |
Česká republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Magyarország Teva Gyógyszergyár Zrt. Tel: +36 12886400 |
Danmark Teva Denmark A/S Tlf: +45 44985511 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Deutschland TEVA GmbH Tel: +49 73140208 | Nederland Teva Nederland B.V. Tel: +31 8000228400 |
Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610801 | Norge Teva Norway AS Tlf: +47 66775590 |
Ελλάδα Specifar A.B.E.E. Τηλ: +30 2118805000 | Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
España Teva Pharma, S.L.U. Tel: +34 913873280 | Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tél: +33 155917800 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda. Tel: +351 214767550 |
Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720000 | România Teva Pharmaceuticals S.R.L. Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Ísland Alvogen ehf. Sími: +354 5222900 | Slovenská republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italia Teva Italia S.r.l. Tel: +39 028917981 | Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805900 |
Κύπρος Specifar A.B.E.E. Ελλάδα Τηλ: +30 2118805000 | Sverige Teva Sweden AB Tel: +46 42121100 |
Latvija UAB Teva Baltics filiale Latvija Tel: +371 67323666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of last revision of this leaflet: {month YYYY}
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
This information is intended only for healthcare professionals or medical staff:
Storage and inspection
Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vial in the outer packaging to protect it from light.
The solution should be allowed to reach a comfortable temperature (15°C – 25°C) for injection.
Once removed from the refrigerator, Lonquex can be stored below 25 °C for a single period of up to 7 days.
The solution must be inspected visually before use. Only clear and colourless solutions without particles should be used.
Vigorous shaking should be avoided. Excessive shaking may cause the lipegfilgrastim to aggregate, making it biologically inactive.
Method of administration
The recommended dose should be injected subcutaneously (SC) using a suitable syringe with the appropriate graduation for the prescribed dose.
The injection should be administered in the abdomen, upper arm, or thigh.
Procedure for proper disposal
Disposal of unused medicine and all materials that have come into contact with it should be done according to local regulations.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LONQUEX 6 mg/0.6 mL Injectable Solution – subject to medical assessment and local rules.